Olema Pharmaceuticals, Inc.
REGIMENS OF ESTROGEN RECEPTOR ANTAGONISTS
Last updated:
Abstract:
Provided herein are methods of administering estrogen receptor antagonists for use in treatment of cancer. In some embodiments, estrogen receptor antagonists provided herein are tetrahydro pyrido[3,4-b] indole compounds. In some embodiments, provided antagonists are complete estrogen receptor antagonists.
Status:
Application
Type:
Utility
Filling date:
6 Jul 2020
Issue date:
25 Aug 2022